Article
Intercept's NASH drug fails late-stage trial, shares tumble
Rating:
0.0
Views:
56
Likes:
1
Library:
1
Intercept Pharmaceuticals Inc said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value